Zobrazeno 1 - 10
of 3 341
pro vyhledávání: ''
Autor:
Daniel M. Berney, Jonathan Shamash, T. Oliver, Anju Sahdev, S. J. Harland, Andrew Gogbashian, Constantine Alifrangis, Gordon J. S. Rustin, Samita Agarwal, Marina Milic, Sarah Duncan, Sara Stoneham, Shafi Chowdhury, Anand Sharma, Michelle Lockley, Peter Wilson
Publikováno v:
European Journal of Cancer. 164:105-113
Background Radiotherapy and cisplatin-based combination chemotherapy are accepted standard-of-care treatments for metastatic seminoma with excellent survival outcomes but with established short- and long-term morbidity. Carboplatin monotherapy may be
Autor:
Anthony M. Joshua, Louise Emmett, Christopher Rofe, Jesse A Ende, Andrew Nguyen, Arnavaz Danesh, Edmond M. Kwan, Lyn Chan, Andrew O. Yam, Shikha Sharma, Megan Crumbaker, Joanne Keane, Sarennya Pathmanandavel, Kamonwan Kongrak, Bao Ho, Peter Eu, Trevor J. Pugh, Arun Azad
Publikováno v:
European Urology Oncology. 4:963-970
Background Trials of lutetium prostate specific membrane antigen (PSMA) in men with metastatic castration-resistant prostate cancer (mCRPC) have demonstrated good safety and efficacy, but combination strategies may improve outcomes. Idronoxil is a sy
Autor:
Guido von Figura, Patrick Wenzel
Publikováno v:
TumorDiagnostik & Therapie. 42:655-661
Ductal pancreatic carcinoma is expected to become one of the most common malignant diseases worldwide in the coming decades. However, the prognosis of the disease remains very poor and has improved only slightly over the last decade. The 5-year survi
Autor:
Sohei Nakayama, Ichiro Maeda, Keita Masuzawa, Yukio Suzuki, Satoshi Tsunematsu, Yusuke Suzuki, Takashi Egawa
Publikováno v:
Internal Medicine
Chemotherapy for multiple primary malignancies is challenging. We herein report a case of synchronous primary lung adenocarcinoma and hepatocellular carcinoma (HCC). A 72-year-old man was admitted for the evaluation of an abnormal shadow on his lung.
Autor:
Nicola Longo, Daniela Terracciano, Francesco Del Giudice, Giuseppe Lucarelli, Angelo Porreca, Pasquale Ditonno, Angelo Luciano, Carlo Buonerba, Alessandro Antonelli, Vincenzo Caputo, Rocco Damiano, Pasquale Dolce, Michele Marchioni, Fabio Crocerossa, Paolo Gontero, Stefania Zamboni, Matteo Manfredi, Antonio Verde, Michele Battaglia, Dario Ribera, Francesco Porpiglia, Gennaro Musi, Francesco Cantiello, Andrea Minervini, Felice Crocetto, Ottavio De Cobelli, Giuseppe Celentano, Vincenzo Cosimato, Mihai Dorin Vartolomei, Nicolae Crisan, Andrea Mari, Giorgio Ivan Russo, Abdal Rahman Abu Farhan, Francesco Greco, Francesco Soria, Francesco Chiancone, Luca Scafuri, Paola Del Prete, Rodolfo Hurle, Pietro De Placido, Giuseppe Di Lorenzo, Sergio Facchini, Matteo Ferro, Riccardo Autorino, Sisto Perdonà, Gian Maria Busetto
Publikováno v:
Future Oncology. 17:3987-3994
The objective of the current research was to explore the potential prognostic value of readily available clinical and pathologic variables in bladder cancer. The novel association found between cholesterol levels and prognosis may provide the rationa
Autor:
Arup Kumar Mandal, Gagan Gautam, Tushar Aditya Narain, Harkirat Singh Talwar, Ankur Mittal, Jyoti Mohan Tosh, Vikas Kumar Panwar
Publikováno v:
Urology. 154:8-15
Neoadjuvant chemotherapy followed by radical cystectomy is the standard of care for muscle invasive non-metastatic bladder cancer patients. While cisplatin based neoadjuvant chemotherapy has been recommended, systemic therapy in a neoadjuvant setting
Publikováno v:
European Urology. 80:123-126
For patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after an androgen receptor axis-targeted therapy and docetaxel, poly (ADP-ribose) polymerase (PARP) inhibitors and chemotherapy with cabazitaxel have shown promise.
Autor:
Mark A. Taylor, Thomas McKaig, Mark Love, Heather Nesbitt, Jinhui Gao, Bridgeen Callan, Anthony P. McHale, John F. Callan, Keiran Logan
Publikováno v:
European Journal of Pharmaceutics and Biopharmaceutics. 165:374-382
Gemcitabine and nab-paclitaxel (Abraxane®) is a standard of care chemotherapy combination used in the treatment of patients with advanced pancreatic cancer. While the combination has shown a survival benefit when compared to gemcitabine monotherapy,
Autor:
Alison Conlin, Thomas Boulet, Georg Kunz, J.C. Alcedo, Andrea Fontana, Irene Wapnir, Norman Wolmark, Xavier Pivot, Max S. Mano, Adam Brufsky, S. Loibl, D. Tesarowski, Chunyan Song, Bella Kaufman, Youngsen Yang, Melanie Smitt, Mahasti Saghatchian, Martina Zimovjanova, Michael Untch, G. von Minckwitz, Jonathan Polikoff, Charles E. Geyer, S. Kuemmel, H. Liu, Eleftherios P. Mamounas, John Hackmann, Lisa H. Lam, C.-S. Huang, T. Kuehn, Michael P. DiGiovanna
Publikováno v:
Annals of Oncology. 32:1005-1014
Background In the KATHERINE study (NCT01772472), patients with residual invasive early breast cancer (EBC) after neoadjuvant chemotherapy (NACT) plus human epidermal growth factor receptor 2 (HER2)-targeted therapy had a 50% reduction in risk of recu
Autor:
Kenneth Russell, Carlos Flores Avile, Patricia Luhn, Stephen Y. Chui, Joyce O'Shaughnessy, Wei Wang, Andreas Schneeweiss, Leisha A. Emens, Shih-Wen Lin
Publikováno v:
Current Oncology, Vol 28, Iss 239, Pp 2741-2752 (2021)
Current Oncology
Volume 28
Issue 4
Pages 239-2752
Current Oncology
Volume 28
Issue 4
Pages 239-2752
We investigated first-line (1L) treatment patterns and predictors of taxane use to better understand the evolving metastatic triple-negative breast cancer (mTNBC) treatment landscape. This retrospective analysis of the Truven Health MarketScan® (Som